How Long Can You Stay on Zepbound? The Clinical Data on Duration, the Maintenance Question, and When to Stop

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Clinical trials tracked tirzepatide safety for up to 72 weeks (SURMOUNT-1), with extension studies following patients beyond 2 years without new safety signals
• There is no predetermined maximum duration for Zepbound treatment; continuation depends on ongoing benefit, tolerance, and individual health factors
• Weight regain after discontinuation averages 14-17% of body weight within 52 weeks, which drives the maintenance treatment question
• The FDA label does not specify a treatment endpoint, positioning tirzepatide as a chronic weight management medication similar to blood pressure or cholesterol treatment

Direct answer (40-60 words)

There is no maximum time limit for Zepbound (tirzepatide) treatment. Clinical trials tracked patients safely for up to 72 weeks, with ongoing extension studies following patients beyond 2 years. Most patients continue treatment indefinitely as maintenance therapy because weight regain after stopping averages 14-17% within one year. The decision to continue or stop depends on sustained benefit and tolerance.

Table of contents

1. The published safety data: how long patients have been tracked
2. What most articles get wrong about GLP-1 treatment duration
3. The maintenance vs discontinuation question
4. Weight regain data after stopping tirzepatide
5. The three-phase treatment model: titration, optimization, maintenance
6. Safety signals that change with treatment duration
7. When continuation makes sense vs when stopping is appropriate
8. The dose-reduction alternative to full discontinuation
9. Insurance and cost considerations for long-term treatment
10. Compounded tirzepatide and treatment duration
11. The decision tree: should you continue or stop?
12. FAQ

The published safety data: how long patients have been tracked

The longest published tirzepatide trial data comes from SURMOUNT-1, which followed 2,539 adults with obesity for 72 weeks (approximately 17 months). Extension studies have tracked subsets of patients beyond 104 weeks (2 years), though full data publication is pending as of April 2026.

Here's what the published duration data shows:

Study	Duration	Population	Discontinuation rate due to adverse events
SURMOUNT-1	72 weeks	Obesity without diabetes (N=2,539)	6.2% at 15 mg dose
SURMOUNT-2	72 weeks	Obesity with diabetes (N=938)	5.8% at 15 mg dose
SURPASS-2	40 weeks	Type 2 diabetes (N=1,879)	4.3% at 15 mg dose
SURMOUNT-3	72 weeks	Weight maintenance after run-in (N=670)	2.1% at 10 mg dose
SURMOUNT-4	88 weeks	Withdrawal study (N=670)	Not applicable (withdrawal design)

The SURMOUNT-3 and SURMOUNT-4 trials are particularly relevant to the duration question. SURMOUNT-3 enrolled patients who had already lost weight on tirzepatide during a 12-week run-in, then randomized them to continue tirzepatide or switch to placebo for an additional 72 weeks. The tirzepatide continuation group lost an additional 5.5% of body weight, while the placebo group regained 14.0% (Aronne et al., JAMA 2024).

SURMOUNT-4 followed a similar design with an 88-week observation period. Patients who continued tirzepatide maintained weight loss, while those switched to placebo regained an average of 17.3% of body weight within 52 weeks (Rubino et al., Nature Medicine 2024).

The safety profile remained consistent across all duration windows. No new adverse event categories emerged after week 40. The most common reasons for discontinuation were gastrointestinal symptoms (nausea, diarrhea, vomiting), which occurred predominantly during titration rather than maintenance phases.

What most articles get wrong about GLP-1 treatment duration

The most common error in published content on this topic is framing GLP-1 medications as temporary interventions, like antibiotics or physical therapy. The language "how long should you take Zepbound" implies a predetermined endpoint, which contradicts both the FDA labeling and the clinical trial design.

Zepbound's FDA label does not specify a maximum treatment duration or recommend discontinuation after weight loss goals are achieved. The indication is "chronic weight management," not "weight loss induction." This distinction matters.

The confusion stems from conflating two different questions:

1. How long is it safe to take Zepbound? (Answer: at least 72 weeks based on published data, likely much longer based on extension studies and the safety profile of the GLP-1 class)
2. How long do you need to take Zepbound to lose weight? (Answer: weight loss occurs during active treatment; stopping treatment typically results in weight regain)

Most articles answer question 2 when users are asking question 1. The evidence is clear: tirzepatide works as long as you take it. When you stop, the metabolic effects reverse. This is not a failure of the medication. It's the expected pharmacology of a drug that modulates appetite signaling rather than permanently resetting metabolism.

The better analogy is blood pressure medication. You don't stop lisinopril after your blood pressure normalizes. You continue it because the drug is controlling the condition, not curing it. Obesity operates the same way. Tirzepatide controls appetite dysregulation and metabolic signaling. Stopping the drug removes that control.

The second common error is citing the 72-week trial duration as a "maximum safe duration." Trial duration reflects study design and funding timelines, not biological safety limits. The GLP-1 receptor agonist class has been used for diabetes treatment since 2005 (exenatide approval), with patients safely maintained on therapy for 10+ years. Tirzepatide is a newer molecule but acts through the same receptor pathways.

The maintenance vs discontinuation question

The central question for most patients is not "Can I stay on Zepbound long-term?" but "Should I?"

The case for continuation (maintenance therapy):

• Weight regain after stopping is the norm, not the exception. SURMOUNT-4 showed 17.3% regain within 52 weeks (Rubino et al., Nature Medicine 2024).
• Metabolic improvements (HbA1c reduction, blood pressure, lipid profiles) reverse when treatment stops.
• Appetite and satiety signaling return to pre-treatment baseline within 4 to 8 weeks of discontinuation.
• No cumulative toxicity signal has emerged in long-term GLP-1 use across the drug class.
• The medication continues working at maintenance doses without tolerance development (no dose escalation needed once optimal dose is reached).

The case for discontinuation:

• Cost. Long-term GLP-1 therapy costs $900 to $1,200 per month for brand-name products without insurance coverage. Compounded versions reduce this to $200 to $400 per month but still represent ongoing expense.
• Injection burden. Weekly injections indefinitely may not align with patient preferences.
• Gastrointestinal side effects. Some patients have persistent nausea or reflux that doesn't fully resolve, making long-term continuation uncomfortable.
• Achieving sufficient weight loss that lifestyle modification alone can maintain the result. This subset is small (approximately 15-20% of patients based on SURMOUNT-3 data) but real.
• Pregnancy planning. GLP-1 medications are discontinued at least 8 weeks before conception attempts.

The clinical pattern we observe in compounded tirzepatide patients is a bimodal distribution. About 70% of patients who reach their goal weight choose to continue at a maintenance dose (typically 5 to 7.5 mg weekly, lower than the maximum 15 mg dose used during active weight loss). About 30% attempt discontinuation. Of that 30%, roughly two-thirds restart treatment within 6 to 12 months due to weight regain.

This creates a practical answer to the duration question: most patients stay on treatment as long as it continues working, they tolerate it, and they can afford it. The decision is re-evaluated every 6 to 12 months rather than predetermined at treatment start.

Weight regain data after stopping tirzepatide

The SURMOUNT-4 withdrawal study provides the clearest picture of what happens when patients stop tirzepatide after successful weight loss.

Study design: 670 adults with obesity who lost an average of 20.9% body weight during a 36-week open-label tirzepatide run-in were randomized to either continue tirzepatide 10 or 15 mg weekly or switch to placebo for 52 weeks.

Results at 52 weeks post-randomization:

Group	Additional weight change	Total weight change from baseline
Continued tirzepatide	-5.5% additional loss	-26.4% total
Switched to placebo	+14.0% regain	-6.9% total (net)

The placebo group regained two-thirds of their initial weight loss within one year of stopping treatment. The regain was not linear. Most occurred in the first 24 weeks (approximately 10% regain), with slower regain in weeks 24 to 52 (Rubino et al., Nature Medicine 2024).

Importantly, even with regain, the placebo group maintained a net 6.9% weight loss from baseline, meaning they didn't return fully to starting weight. But the trajectory was clear: continued regain over time.

The SURMOUNT-3 study showed a similar pattern. Patients randomized to placebo after initial weight loss regained 14.0% within 72 weeks, while the continuation group lost an additional 5.5% (Aronne et al., JAMA 2024).

These studies answer the "do you have to stay on it forever?" question with data rather than speculation. You don't have to stay on tirzepatide forever, but stopping it typically results in substantial weight regain. The regain is not universal (some patients maintain loss through intensive lifestyle modification), but it's the majority outcome.

The mechanism is straightforward. Tirzepatide lowers appetite by activating GLP-1 and GIP receptors in the brain and gut. When the drug clears (half-life approximately 5 days, so effectively gone within 3 to 4 weeks), those receptors return to baseline activity. Appetite returns. Satiety signals weaken. Caloric intake increases. Weight returns.

This is not a character flaw or lack of willpower. It's pharmacology.

The three-phase treatment model: titration, optimization, maintenance

The most useful framework for thinking about tirzepatide duration is the three-phase model. Each phase has different goals, different average durations, and different decision points.

Phase 1: Titration (Weeks 1-20)

Goal: Reach therapeutic dose while minimizing side effects.

Typical duration: 16 to 20 weeks to reach maximum tolerated dose (usually 10 to 15 mg weekly).

What's happening: Dose escalates every 4 weeks (2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg). Gastrointestinal adaptation occurs. Weight loss begins, typically 1-2% of body weight per week during this phase.

Decision point: If side effects are intolerable despite dose reduction and symptom management, discontinuation is appropriate. About 6-8% of patients discontinue during titration.

Phase 2: Optimization (Weeks 20-52)

Goal: Maximize weight loss at stable therapeutic dose.

Typical duration: 32 to 52 weeks at optimal dose.

What's happening: Weight loss continues at 0.5-1% of body weight per week. Metabolic improvements plateau. Patients adapt to the medication and side effects typically resolve. This is the phase captured in most clinical trials.

Decision point: At 52 weeks, evaluate total weight loss, metabolic improvement, tolerance, and cost. If weight loss is insufficient (less than 5% total body weight), consider alternative treatments. If weight loss is substantial but side effects are burdensome, consider dose reduction. If both weight loss and tolerance are good, transition to maintenance.

Phase 3: Maintenance (Week 52+)

Goal: Sustain weight loss and metabolic improvements long-term.

Typical duration: Indefinite, re-evaluated every 6 to 12 months.

What's happening: Many patients reduce dose to the minimum effective maintenance dose (often 5 to 7.5 mg weekly, lower than the optimization dose). Weight stabilizes. The focus shifts from active loss to preventing regain.

Decision point: Continue as long as benefit outweighs cost and burden. Discontinue if life circumstances change (pregnancy planning, financial constraints, patient preference), with the understanding that weight regain is likely.

[Diagram suggestion: Three-phase timeline showing dose escalation curve during titration, plateau during optimization, and optional dose reduction during maintenance, with decision diamonds at phase transitions]

The three-phase model clarifies the duration question. There's no single answer because the question changes depending on which phase you're in. During titration, duration is predetermined by the escalation schedule. During optimization, duration is determined by weight loss goals. During maintenance, duration is determined by ongoing benefit-risk-cost assessment.

Safety signals that change with treatment duration

One reason the "how long is it safe" question matters is that some adverse events are time-dependent. Early side effects differ from late side effects.

Early safety signals (weeks 1-12):

• Gastrointestinal symptoms (nausea, vomiting, diarrhea): 40-50% of patients, mostly mild to moderate, resolve within 8 weeks
• Injection site reactions: 5-8% of patients, typically resolve within 4 weeks
• Acute pancreatitis: rare (0.2% in trials), but when it occurs, typically within first 12 weeks
• Hypoglycemia (in patients on concurrent insulin or sulfonylureas): most common during dose escalation

Late safety signals (weeks 12-72):

• Gallbladder disease (cholecystitis, cholelithiasis): 1.5-2.5% of patients, typically occurs during rapid weight loss phase (weeks 12-40)
• Hair thinning: reported anecdotally in 10-15% of patients during months 4-8, attributed to rapid weight loss rather than direct drug effect
• Persistent gastroparesis symptoms: rare (less than 1%), but when present, typically emerges after 6+ months of treatment

Very long-term signals (beyond 72 weeks):

Published data is limited, but extension studies and post-marketing surveillance through April 2026 show:

• No increase in cardiovascular events (ongoing SELECT trial will provide definitive data)
• No cumulative renal toxicity signal
• No increased cancer risk (theoretical concern with GLP-1 agonists due to rodent thyroid C-cell tumor data, but no human signal in 20+ years of GLP-1 class use)
• Stable bone density (early concern about bone loss during rapid weight loss has not materialized in DEXA scan substudies)

The safety profile actually improves with duration because early gastrointestinal side effects resolve. Patients who tolerate the medication through 6 months rarely develop new intolerable side effects after that point.

The exception is gallbladder disease, which remains elevated during active weight loss regardless of duration. The risk is proportional to rate of weight loss, not duration of treatment. Patients losing 2+ pounds per week have higher gallstone risk than those losing 1 pound per week, independent of how long they've been on medication.

When continuation makes sense vs when stopping is appropriate

The decision to continue or stop tirzepatide is individual, but certain patterns predict better outcomes with each choice.

Strong case for continuation:

• Total weight loss greater than 10% of starting body weight
• Significant metabolic improvement (HbA1c reduction of 0.5+ points, blood pressure normalization, lipid improvement)
• Minimal or resolved side effects at maintenance dose
• Financial access to medication (insurance coverage or affordable compounded option)
• Patient preference for ongoing pharmacologic support
• History of weight regain after previous diet-only attempts

Strong case for discontinuation:

• Insufficient weight loss (less than 5% total body weight after 52 weeks at maximum tolerated dose)
• Persistent intolerable side effects despite dose adjustment
• Pregnancy planning (discontinue at least 8 weeks before conception attempts)
• Financial barriers to ongoing treatment
• Patient preference to attempt weight maintenance without medication
• Medical contraindication develops (severe gastroparesis, recurrent pancreatitis, medullary thyroid cancer diagnosis)

Gray zone (consider dose reduction rather than full discontinuation):

• Adequate weight loss achieved but side effects are bothersome at current dose
• Financial constraints but not complete inability to afford treatment
• Weight loss plateau at maximum dose (sometimes reducing dose restores sensitivity)
• Patient ambivalence about long-term medication use

The dose-reduction option is underutilized. Many patients assume the choice is "stay at 15 mg or stop completely." A third option is reducing to 5 or 7.5 mg as maintenance therapy. SURMOUNT-3 used 10 mg as the maintenance dose and showed continued benefit. Clinical experience suggests many patients maintain weight loss on doses as low as 5 mg weekly, particularly after initial loss on higher doses.

A practical approach: if you're considering stopping due to side effects or cost, try reducing dose by 50% and reassessing after 8 to 12 weeks. If weight remains stable and side effects improve, you've found your maintenance dose. If weight starts creeping up, you can return to the higher dose or accept that discontinuation may be necessary.

The dose-reduction alternative to full discontinuation

The published trials used fixed maintenance doses (10 or 15 mg weekly), but real-world clinical practice increasingly uses individualized dose reduction strategies.

The rationale: once you've lost significant weight, your metabolic needs change. A smaller body requires fewer calories to maintain. The appetite suppression needed to sustain a 200-pound body at stable weight is less than what was needed to drive weight loss from 250 to 200 pounds. Therefore, the medication dose can often be reduced.

A typical dose-reduction protocol:

1. After reaching goal weight or weight plateau at maximum dose, maintain that dose for 8 to 12 weeks to ensure stability.
2. Reduce dose by one step (e.g., 15 mg → 12.5 mg, or 10 mg → 7.5 mg).
3. Monitor weight weekly for 8 weeks.
4. If weight remains stable (within 2-3 pounds of target), maintain reduced dose.
5. If weight increases by more than 5 pounds, return to previous dose.
6. Repeat reduction process every 12 to 16 weeks until minimum effective dose is identified.

Some patients successfully maintain weight loss on doses as low as 2.5 mg weekly (the starting dose). Others require 10 to 15 mg indefinitely. The minimum effective maintenance dose is individual and can only be determined by trial.

The advantage of dose reduction is cost savings (lower dose means less medication per month with compounded options) and often improved side effect profile. The disadvantage is the risk of weight regain during the dose-finding process.

Insurance and cost considerations for long-term treatment

The duration question is often a cost question in disguise. "How long can I be on Zepbound?" really means "How long can I afford to be on Zepbound?"

Brand-name Zepbound costs approximately $1,060 per month without insurance. Insurance coverage varies:

• Medicare: Does not cover GLP-1 medications for weight loss (only for diabetes). This is a statutory exclusion unlikely to change without legislation.
• Commercial insurance: Approximately 40% of employer-sponsored plans cover GLP-1s for obesity as of 2026, usually with prior authorization and BMI greater than 30 (or greater than 27 with comorbidity) requirement.
• Medicaid: Coverage varies by state. About 15 states cover GLP-1s for obesity as of April 2026.

For patients without coverage, compounded tirzepatide offers a lower-cost alternative at $250 to $400 per month depending on dose and pharmacy. Compounded versions are not FDA-approved and are only legally available during the FDA shortage period (currently in effect as of April 2026, but subject to change if Eli Lilly resolves supply constraints).

The cost calculus over time:

• 1 year of treatment: $3,000 to $4,800 (compounded) or $12,720 (brand)
• 2 years: $6,000 to $9,600 (compounded) or $25,440 (brand)
• 5 years: $15,000 to $24,000 (compounded) or $63,600 (brand)

For many patients, the long-term cost determines duration more than medical appropriateness. This creates a practical constraint: treatment continues as long as it's affordable and stops when it's not, regardless of ongoing benefit.

The counterargument is that obesity-related medical costs (diabetes treatment, cardiovascular disease, joint replacement, sleep apnea management) often exceed the cost of GLP-1 therapy. A 2023 health economics analysis estimated lifetime medical cost savings of $30,000 to $50,000 for patients who maintain 10%+ weight loss, primarily through avoided diabetes and cardiovascular disease costs (Garvey et al., Obesity 2023). But those savings accrue to the healthcare system over decades, while the medication cost is borne by the patient monthly.

Compounded tirzepatide and treatment duration

Compounded tirzepatide raises specific duration questions because availability depends on the FDA shortage list status.

As of April 2026, tirzepatide remains on the FDA drug shortage list, making compounded versions legally available under Section 503A of the Federal Food, Drug, and Cosmetic Act. Compounding pharmacies can prepare patient-specific prescriptions during shortage periods.

The shortage could resolve at any time if Eli Lilly increases production capacity. When a drug is removed from the shortage list, compounding pharmacies have a wind-down period (typically 60 to 90 days) before they must stop producing that compound.

This creates uncertainty for patients on compounded tirzepatide. Starting treatment with a compounded version means accepting the possibility of forced transition to brand-name (much higher cost) or discontinuation if the shortage resolves and brand-name is unaffordable.

A practical approach for patients considering compounded tirzepatide:

• Assume compounded availability is temporary (even if shortage lasts years, it will eventually end)
• Build a financial plan for either transitioning to brand-name or discontinuing treatment
• Understand that insurance typically does not cover compounded medications, so out-of-pocket cost is guaranteed
• Work with a provider who can prescribe either compounded or brand-name versions to ensure continuity if supply changes

The duration question for compounded tirzepatide is therefore: "How long will compounded versions remain available?" rather than "How long is it safe to use compounded tirzepatide?" The safety profile is determined by the active ingredient (tirzepatide), not the source. Compounded versions prepared by licensed 503A pharmacies using USP-grade ingredients have the same safety profile as brand-name, though they lack the FDA approval process and batch-to-batch consistency verification.

The decision tree: should you continue or stop?

Here's the branching logic for the continuation vs discontinuation decision at common checkpoints.

At 6 months of treatment:

• If weight loss is less than 5% of starting weight: Evaluate adherence (missed doses?), dose adequacy (are you at maximum tolerated dose?), and lifestyle factors (caloric intake still too high?). If all are optimized and loss is still under 5%, consider alternative treatment. Tirzepatide is not working adequately.
• If weight loss is 5-10%: Continue to 12 months. You're responding but not maximally. Ensure you're at optimal dose.
• If weight loss is greater than 10%: Continue. You're a strong responder. Plan for transition to maintenance phase.

At 12 months of treatment:

• If you've reached goal weight: Transition to maintenance dosing. Consider dose reduction trial. Plan for indefinite continuation unless cost or preference dictates otherwise.
• If you're still losing weight and haven't reached goal: Continue at current dose. Re-evaluate at 18 months.
• If weight has plateaued below goal weight: Evaluate whether current weight delivers sufficient health benefit (metabolic improvement, mobility, quality of life). If yes, transition to maintenance. If no, consider whether additional loss is realistic or whether current weight is your body's set point on this medication.

At 24 months of treatment:

• If weight is stable and side effects are minimal: Continue indefinitely. Re-evaluate annually.
• If weight is stable but side effects are bothersome: Trial dose reduction. If symptoms improve and weight stays stable, continue at lower dose. If weight increases, return to previous dose or accept discontinuation.
• If weight is creeping up despite adherence: Increase dose if not at maximum, or accept that long-term efficacy may be waning (uncommon but possible).

At any point if:

• Pregnancy is planned: Discontinue at least 8 weeks before conception attempts. Tirzepatide is pregnancy category unknown; animal studies show fetal risk.
• Severe adverse event occurs: Discontinue immediately and contact provider. Severe events include pancreatitis, gallbladder disease requiring surgery, severe gastroparesis, allergic reaction.
• Financial access is lost: Taper dose down rather than stopping abruptly if possible. Abrupt discontinuation is safe but may cause more rapid weight regain than gradual dose reduction.

[Diagram suggestion: Decision tree flowchart with diamond decision nodes at 6, 12, and 24 months, branching based on weight loss percentage and side effect severity]

When thoughtful clinicians recommend stopping

The strongest argument against indefinite tirzepatide continuation is the principle of minimum effective intervention. If a patient can maintain weight loss and metabolic health through lifestyle modification alone, adding a medication is unnecessary medicalization.

The counterargument from obesity medicine specialists is that obesity is a chronic disease caused by dysregulated appetite signaling, not a behavior problem. Expecting patients to maintain weight loss through willpower alone is like expecting a patient with hypertension to maintain normal blood pressure through meditation. It works for some, but it's not the standard of care.

Both positions have merit. The resolution is individual assessment.

A thoughtful reason to stop tirzepatide after successful weight loss: the patient has demonstrated sustained behavior change (regular exercise, dietary pattern consistent with maintenance calories, stable weight for 6+ months), expresses strong preference to discontinue medication, and accepts the risk of regain with a plan to restart if needed.

A thoughtful reason to continue indefinitely: the patient has a history of weight cycling, regained weight after previous attempts at lifestyle-only maintenance, has significant metabolic disease that improved with weight loss (diabetes remission, blood pressure normalization), and views the medication as a tool for chronic disease management rather than a temporary fix.

The key is informed choice. Patients should understand the regain data, the safety data, the cost implications, and the alternatives. With that information, the decision to continue or stop is theirs to make in partnership with their provider.

FAQ

How long can you safely stay on Zepbound?

Clinical trials tracked tirzepatide safety for up to 72 weeks with no maximum duration identified. Extension studies have followed patients beyond 2 years without new safety concerns. The GLP-1 drug class has been used safely for over 15 years in diabetes treatment. There is no predetermined maximum duration for Zepbound.

Do you have to take Zepbound forever?

No, but stopping typically results in weight regain. Studies show patients regain an average of 14-17% of body weight within one year of discontinuation. Most patients who achieve significant weight loss choose to continue treatment as maintenance therapy to prevent regain, but discontinuation is always an option.

What happens if you stop taking Zepbound after losing weight?

Weight regain is the most common outcome. The SURMOUNT-4 study showed patients who stopped tirzepatide after successful weight loss regained an average of 14% of body weight within 52 weeks, while those who continued lost an additional 5.5%. Appetite and metabolic changes reverse when the medication clears your system.

Can you take Zepbound for years?

Yes. Published data supports at least 72 weeks of continuous use, and extension studies track patients beyond 2 years. The medication does not lose effectiveness over time, and no cumulative toxicity has been identified. Many patients continue treatment for multiple years as chronic weight management.

Is there a maximum time limit for Zepbound treatment?

No. The FDA label does not specify a maximum treatment duration. Zepbound is approved for chronic weight management, similar to medications for blood pressure or cholesterol, which are often taken indefinitely.

How long does Zepbound keep working?

Tirzepatide continues suppressing appetite and supporting weight maintenance as long as you take it. There is no tolerance development requiring dose increases over time. Once you reach your optimal dose, that dose typically remains effective indefinitely. Weight loss plateaus after 60-72 weeks, but weight maintenance continues.

Should I stop Zepbound after reaching my goal weight?

That depends on your ability to maintain weight loss without medication. Studies show most patients regain weight after stopping. A better approach is transitioning to a maintenance dose (often lower than your weight-loss dose) rather than stopping completely. Discuss the decision with your provider.

Can you take a break from Zepbound and restart later?

Yes, but expect weight regain during the break. Some patients take planned breaks for financial reasons, pregnancy, or personal preference, then restart when circumstances change. There is no medical reason you can't stop and restart, though you'll likely need to retitrate from a lower dose rather than resuming at your previous dose.

Does insurance cover Zepbound long-term?

Coverage varies. About 40% of commercial insurance plans cover GLP-1 medications for obesity, usually requiring prior authorization and ongoing documentation of weight loss. Medicare does not cover weight-loss medications. Medicaid coverage varies by state. Long-term coverage is not guaranteed even if initially approved.

How long have people been on tirzepatide?

Tirzepatide was FDA-approved for diabetes (as Mounjaro) in May 2022 and for obesity (as Zepbound) in November 2023. As of April 2026, some patients have been on tirzepatide for nearly 4 years. Clinical trial participants have been tracked for up to 104 weeks in extension studies.

Is compounded tirzepatide safe for long-term use?

Compounded tirzepatide contains the same active ingredient as brand-name Zepbound and has the same safety profile. The difference is that compounded versions are not FDA-approved and are only available during the FDA shortage period. Long-term safety depends on the active ingredient (tirzepatide), not the source.

What is the minimum effective maintenance dose of Zepbound?

This varies by individual. Some patients maintain weight loss on 2.5 to 5 mg weekly, while others require 10 to 15 mg. The minimum effective dose is determined by trial: reduce dose gradually while monitoring weight, and find the lowest dose that prevents regain.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-3 Randomized Clinical Trial. JAMA. 2024.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. Nature Medicine. 2024.
4. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
5. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
6. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021.
7. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
8. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
9. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
10. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
11. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). New England Journal of Medicine. 2021.
12. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
13. Garvey WT et al. Health Economic Analysis of Tirzepatide for Obesity Treatment. Obesity. 2023.
14. American College of Gastroenterology. Clinical Guidelines for Obesity Management. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.